Wogonin-Loaded PLGA Sustained-Release Nanomicelle Inhibiting EGFR Pathway for Antitumor Effects in OSCC Authors: Leina Gao, Dixin Cui, Xu Gao, Xiaoling Luan, Huali Gao Published: 2026 ABSTRACT Oral squamous cell carcinoma (OSCC) is the most prevalent malignancy of the head and neck. Current treatment strategies, including surgery, radiotherapy, and chemotherapy, are limited by moderate efficacy and severe side effects, highlighting the need for novel therapeutic approaches. Wogonin (Wo), a natural flavonoid, has shown antiproliferative, pro-apoptotic, and antimetastatic activities in various cancer models; however, its effect on OSCC has not been investigated. In this study, Wo-loaded poly­(lactic-co-glycolic acid) nanoparticles (PW NPs) were prepared to enhance water solubility and achieve sustained drug release. In vitro assays, including CCK-8, flow cytometry, live/dead staining, and wound healing assays, revealed that PW NPs significantly inhibited OSCC cell proliferation, induced apoptosis, and reduced cell migration. Network pharmacology analysis and qRT-PCR further suggested that Wo exerts its therapeutic effects through the EGFR signaling pathway. Hemolysis testing and histological examination of major organs confirmed the favorable biocompatibility of the nanoparticles. This study provides the first systematic evidence of the therapeutic potential of Wo in OSCC and lays a foundation for its further preclinical development. Introduction Oral squamous cell carcinoma (OSCC) is one of the most common malignancies of the head and neck, with an annual global incidence of approximately 8.7 per 100,000, and disproportionately high rates in Asia. − According to the Global Cancer Burden report, the five-year survival rate of OSCC in Asia is only 50%–60%, reflecting poor clinical outcomes. − Standard treatments, including surgery, radiotherapy, and chemotherapy, often result in oral dysfunction, mucositis, and myelosuppression, which severely compromise the quality of life of patients. − Despite advances in therapeutic technologies, the overall survival rate has not improved significantly over the past decades, underscoring the urgent need for safer and more effective treatment strategies. − Natural plant-derived compounds have attracted considerable attention in oncology research due to their multitarget mechanisms, low systemic toxicity, and diverse biological activities. , Wogonin (Wo), a flavonoid extracted from Scutellaria baicalensis, has demonstrated potent antitumor effects in various cancer types, including breast, lung, liver, and gastric cancers. − These effects include inhibition of cell proliferation, induction of apoptosis, suppression of invasion and metastasis, and enhancement of chemosensitivity. Mechanistic studies suggest that Wo modulates multiple signaling pathways, including PI3K/AKT, NF-κB, MAPK, and Wnt/β-catenin, and also regulates immune responses within the tumor microenvironment. − Despite these promising findings, the effects and molecular mechanisms of Wo in OSCC remain unexplored, making it a crucial candidate for further investigation. The clinical application of Wo is limited by its poor water solubility, low bioavailability, and rapid metabolism, which hinder its therapeutic efficacy in vivo. Nanocarrier systems offer a promising approach to address these challenges by improving drug solubility, enabling sustained release, prolonging circulation time, and enhancing tissue distribution and cellular uptake. , Among various drug delivery systems, poly­(lactic-co-glycolic acid) (PLGA) nanoparticles have emerged as ideal carriers due to their biocompatibility, biodegradability, and controlled release capabilities. − Therefore, the development of Wo-loaded PLGA nanoparticles is expected to significantly enhance the therapeutic efficacy of Wo by improving its pharmacokinetic profile and targeting capabilities, thus offering a novel strategy for overcoming its limitations in clinical application. In this study, Wo-PLGA nanoparticles (PW NPs) were developed (Scheme A), and their physicochemical properties, release behavior, cytotoxicity, and biocompatibility were systematically evaluated. In vitro experiments demonstrated that PW NPs effectively inhibited the proliferation, induced apoptosis, and reduced migration of OSCC cells. Hemolysis testing and histological analysis of major organs in mice further confirmed the biocompatibility of PW NPs. These results indicate that PW NPs not only inhibit OSCC cell proliferation and migration but also induce apoptosis, while showing good in vivo safety. Additionally, network pharmacology analysis was used to identify potential molecular targets and signaling pathways associated with Wo’s antitumor effects. The results indicated that PW NPs exert antitumor effects by regulating the EGFR signaling pathway (Scheme B), further supporting WP as a promising therapeutic strategy for OSCC. Collectively, these findings provide strong evidence for the therapeutic potential of Wo in OSCC and establish a foundation for future preclinical studies. PLGA-Wogonin Nanoparticles Induce Apoptosis in Oral Squamous Cell Carcinoma (OSCC) Cells by Inhibiting the EGFR Pathway a(A) Schematic representation of the preparation of PLGA-Wogonin nanoparticles; (B) PW NPs induce apoptosis in OSCC cells by inhibiting the EGFR pathway. (A) Schematic representation of the preparation of PLGA-Wogonin nanoparticles; (B) PW NPs induce apoptosis in OSCC cells by inhibiting the EGFR pathway. Experimental Section Materials Wogonin (W101155, ≥98%), poly­(vinyl alcohol) (13–23 kDa, 99%, AR), and Tween 80 (T485985, AR) were purchased from Shanghai Aladdin Biochemical Technology Co., Ltd. (Aladdin Scientific). Acetone was purchased from China National Pharmaceutical Group Co., Ltd. (Sinopharm), and poly­(lactic-co-glycolic acid) (PLGA) was obtained from Sigma-Aldrich. Phosphate-buffered saline, 4% paraformaldehyde, Cell Counting Kit-8 (C0037), Beyo3D Calcein/PI Cell Viability/Cytotoxicity Assay Kit (C1371S), Annexin V-APC Apoptosis Detection Kit (C1062S), RNA/DNA Isolation Kit (R0017S), and BeyoFast SYBR Green One-Step qRT-PCR Kit (D7268S) were purchased from Beyotime Biotechnology. All reagents were used as received without further purification. Preparation of PW NPs PW NPs were prepared using the emulsion solvent evaporation method with slight modifications. Briefly, PLGA (4 mg) and wogonin (1 mg) were dissolved in acetone (0.2 mL) and stirred until thoroughly mixed. The organic phase was then slowly dropped into a 1% poly­(vinyl alcohol) (PVA) aqueous solution, followed by ultrasonication in an ice bath for 5 min to form an emulsion. The emulsion was magnetically stirred for 4 h to allow solvent evaporation. PW NPs were subsequently collected by centrifugation and washed three times with ultrapure water. Finally, the PW NPs were freeze-dried and stored as powder at −20 °C. Characterization of PW NPs The morphology of PW NPs was observed by transmission electron microscopy (TEM, JEM-2100UHR, JEOL, Japan) and scanning electron microscopy (SEM, VEGA3, TESCAN Co., Ltd., Shanghai, China). The average particle size and zeta potential of the nanoparticle dispersion were determined using a Malvern Zetasizer (Nano ZS, Malvern, U.K.). Fourier transform infrared spectroscopy (FT-IR) was performed at room temperature with a NICOLET iS10 spectrometer. The characteristic absorption spectra were obtained using a UV–visible spectrophotometer (UV-8000, Shanghai Metash Instruments Co., Ltd.). The drug loading capacity and encapsulation efficiency of PW NPs were quantified by UV–visible spectrophotometry. The encapsulation rate and drug loading capacity are calculated as follows encapsulationrate=weightofwogoninloadedintotheNPsweightofthetotaldrugadded×100% drugloadingcapacity=weightofwogoninloadedintotheNPstotalweightoftheNPs×100% In Vitro Drug Release The in vitro release behavior of wogonin from PW NPs was evaluated using the dialysis bag method. Briefly, 5 mg of PW NPs was suspended in 2 mL phosphate-buffered saline (PBS) and transferred into a dialysis bag (molecular weight cutoff: 12,000–14,000 Da). The sealed bag was immersed in 50 mL PBS (pH 7.4) containing 1% Tween 80 and maintained at 37 °C under constant stirring at 100 rpm. At different time points (1, 2, 3, 4, 6, 8, 10, 12, 24, and 48 h), 1 mL of release medium was withdrawn, and the concentration of wogonin was determined spectrophotometrically at 278 nm. To maintain sink conditions, an equal volume of fresh PBS was replenished after each sampling. Cell Culture Human Oral Keratinocytes (HOK) and Cal-27 cells were purchased from Wuhan Procell Biotechnology Co., Ltd.. Both HOK cells and Cal-27 cells were cultured in a special medium containing endothelial cell growth factor (SUNNCELL, China), 10% fetal bovine serum (FBS), 1% penicillin (50 U/mL), and 1% streptomycin (50 U/mL). The cells were maintained in a standard humidified cell culture incubator at 37 °C with 5% CO2. Cytotoxicity and Biocompatibility Assays Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay to evaluate the cytotoxicity of PW NPs against oral squamous carcinoma cells (Cal-27) and their biocompatibility with normal human oral keratinocytes (HOK). Cal-27 or HOK cells were seeded at a density of 10,000 cells per well in 96-well plates and incubated for 24 h to allow attachment. The culture medium was then replaced with fresh medium containing various concentrations of PW NPs (25, 50, 100, 200, and 300 μg/mL), followed by incubation for an additional 24 h. CCK-8 reagent was then added according to the manufacturer’s instructions, and the absorbance was measured at 450 nm using a microplate reader to determine cell viability. The cell viability (%) was calculated using the following formula cell viability(%)=(ODsample−ODblankODcontrol−ODblank)×100% Live/Dead Cell Staining Assay The viability of Cal-27 cells after PW NPs treatment was assessed using a live/dead cell staining assay. Briefly, Cal-27 cells were seeded in confocal culture dishes and incubated for 24 h. The medium was then replaced with fresh medium containing PW NPs at concentrations of 25, 50, 100, 200, and 300 μg/mL. After 24 h of incubation, cells were washed with PBS and stained with Calcein-AM and propidium iodide (PI) according to the manufacturer’s protocol. Fluorescence images were captured using a confocal laser-scanning microscope, in which live cells emitted green fluorescence and dead cells emitted red fluorescence. Flow Cytometry Apoptosis Assay Apoptosis in Cal-27 cells was assessed using Annexin V-APC/PI double staining followed by flow cytometry. Cal-27 cells were seeded in 12-well plates (three replicate wells per concentration) and incubated for 24 h, then treated with PW NPs at 25, 50, 100, 200, and 300 μg/mL for an additional 24 h. After treatment, cells were harvested, washed twice with cold PBS, and resuspended in binding buffer. Annexin V-APC and PI were added according to the manufacturer’s instructions, and samples were analyzed by flow cytometry to determine the proportions of viable, early apoptotic, late apoptotic, and necrotic cells. Wound Healing Assay The migratory ability of Cal-27 cells after PW NPs treatment was evaluated using the wound healing assay. Cal-27 cells were seeded in 6-well plates and cultured until reaching confluence. A sterile pipet tip was used to create a straight scratch across the cell monolayer, and PBS was used to remove detached cells. The medium was then replaced with serum-free medium containing PW NPs at concentrations of 25, 50, 100, 200, and 300 μg/mL. Images of wound closure were captured at 0, 24, and 48 h using an inverted microscope. Migration ability was quantified by measuring wound area at each time point and calculating the relative reduction compared with the initial wound area. Network Pharmacology Analysis Potential gene targets of wogonin were obtained from the PharmMapper database (https://www.lilab-ecust.cn/pharmmapper/), while OSCC-related targets were retrieved from the GeneCards database (https://www.genecards.org/). The overlapping targets were identified and imported into the STRING database (https://cn.string-db.org/), with the species set to Homo sapiens and the interaction confidence score set at 0.400 (medium confidence), to construct a protein–protein interaction (PPI) network. For detail, 108 potential antitumor targets of Wo were identified from the PharmMapper database, with a Norm Fit score greater than 0.5. Additionally, 2592 OSCC-related targets were retrieved from the GeneCards database. The CytoHubba plugin in Cytoscape was then applied to screen hub targets. The intersected targets were further analyzed for KEGG pathway enrichment, and key pathways were identified. Finally, core targets within these pathways were validated by differential expression analysis using the GEO database (GSE23558). Quantitative Real-Time PCR (qRT-PCR) The expression of EGFR was analyzed in four groups: HOK, Cal-27, Cal-27 treated with free wogonin (Cal-27 + Wo), and Cal-27 treated with PW NPs (Cal-27 + PW). For drug-treated groups, cells were incubated with 100 μg/mL of wogonin or PW NPs for 24 h before RNA extraction. Total RNA was isolated using TRIzol reagent, and the concentration and purity were determined spectrophotometrically. cDNA was synthesized from 1 μg of RNA using a reverse transcription kit. qRT-PCR was performed with SYBR Green Master Mix on a real-time PCR system under standard cycling conditions. GAPDH served as the internal control. Relative expression levels of EGFR were calculated using the 2∧−ΔΔCt method. The primer sequences used are shown in Table : 1Primer Sequences of EGFR and GAPDH for qRT-PCRprimerforwardreverseEGFR5′-AACACCCTGGTCTGGAAGTACG–3′5′-TCGTTGGACAGCCTTCAAGACC–3′GAPDH5′-CTGACTTCAACAGCGACACC–3′5′-TAGCCAAATTCGTTGTCATACC–3′ Primer Sequences of EGFR and GAPDH for qRT-PCR The qRT-PCR conditions were: initial denaturation at 95 °C for 3 min, followed by 40 cycles of 95 °C for 15 s, 60 °C for 30 s, and 72 °C for 30 s, with a final extension at 72 °C for 5 min. Each experiment was performed in triplicate. Hemolysis Assay The hemolytic activity of PW NPs was evaluated using fresh mouse red blood cells. Six groups were included: PBS (negative control), distilled water (DW, positive control), and PW NPs at concentrations of 25, 50, 100, and 200 μg/mL. Freshly collected red blood cells were washed with PBS and resuspended to prepare a 4% suspension. 200 μL red blood cell suspension and 200 μL samples were mixed and incubated at 37 °C for 2 h. After centrifugation, the supernatant was collected, and absorbance at 540 nm was measured with a microplate reader to calculate the hemolysis rate. hemolysis rate=(ODsample−ODnegativeODpositive−ODnegative)×100% Toxicological Analysis To evaluate the in vivo toxicity, healthy mice were intravenously injected with PW NPs at a dose of 100 μg/mL (100 μL PBS solution, one time). After 7 days of treatment, the animals were sacrificed by exposure to a 100% CO2 atmosphere in a sealed chamber. The animals were then euthanized, and major organs, including the heart, liver, spleen, lungs, and kidneys, as well as blood samples, were collected. Blood samples were analyzed for complete blood count (CBC) and serum biochemistry to assess potential systemic toxicity. Tissue samples were fixed in 4% paraformaldehyde, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). Histopathological changes were examined under a light microscope to assess potential tissue damage or toxicity. Statistical Analysis All data were analyzed using one-way analysis of variance (ANOVA) to compare group differences. Statistical significance was determined based on the ANOVA results, using GraphPad Prism 9.5 software. The number of replicates for each experiment is indicated in the figure legends. Data are presented as mean ± standard deviation (SD). Statistical significance was set at p < 0.05. Results and Discussion Preparation and Characterization of PW NPs PW NPs were successfully prepared using the nanoemulsion–solvent evaporation method, and their morphology, particle size, surface charge, spectral features, and release behavior were systematically characterized. Scanning electron microscopy (SEM, Figure a) revealed that the PW NPs exhibited a uniform spherical morphology with smooth surfaces. Transmission electron microscopy (TEM, Figure b) further confirmed the spherical structure and homogeneous distribution of the PW NPs; the inset (upper right) shows the particle size distribution, with a peak at 100–120 nm. By establishing a standard curve for wogonin and measuring the absorbance spectra of the drug-loaded nanoparticles (Figure c-e), the encapsulation efficiency and drug loading capacity of PLGA nanoparticles for wogonin were determined to be 76.74% and 15.34%, respectively. Dynamic light scattering (DLS, Figure f) indicated that the PW NPs had a hydrated particle size of 194 nm and a PDI of 0.18, suggesting good dispersion and a narrow size distribution in aqueous solution. Zeta potential measurements (Figure f) showed that the blank PLGA NPs carried a slight positive charge (+0.299 ± 0.02 mV). In contrast, the PW NPs exhibited a negative charge (−6.87 ± 0.69 mV), confirming successful drug loading and its influence on surface charge. Ultraviolet–visible (UV–vis, Figure g) spectra revealed a characteristic absorption peak of wogonin at 278 nm, which was also observed in the PW NPs. In contrast, the blank PLGA NPs displayed no distinct peak, further confirming effective drug encapsulation. Fourier-transform infrared (FT-IR, Figure h) spectra revealed that the PW NPs retained the characteristic peaks of PLGA, while displaying additional peaks corresponding to the CO and O–H stretching vibrations of Wogonin. The FT-IR analysis identified three key differences between PLGA, Wogonin, and PW NPs. The peaks in the 1000–1250 cm–1 and around 1750 cm–1 regions, which are typical of PLGA, were also present in PW NPs, confirming the retention of PLGA’s ester group stretching and CO vibration. However, a significant difference was observed in the 3100–3250 cm–1 region. Wogonin exhibited a broad O–H stretching vibration in this region, typical of hydroxyl groups. In contrast, PW NPs showed a distinct peak at a lower wavenumber (around 3000 cm–1), suggesting a shift in the O–H stretching vibration due to interactions between the hydroxyl groups of Wogonin and the PLGA matrix. This shift indicates that the encapsulation of Wogonin within the PLGA matrix affects the hydrogen bonding and the overall molecular environment of the O–H group. Next, we conducted an in vitro drug release study to calculate the drug release percentage based on the drug loading capacity, which was set as 100%. The release profile (Figure i) showed that approximately 40% of wogonin was released within 12 h, 65% within 24 h, and 85% within 48 h, indicating sustained release. Collectively, the prepared PW NPs exhibited uniform spherical morphology, favorable aqueous dispersion, and stable sustained-release properties, providing a robust foundation for subsequent pharmacological evaluation and mechanistic studies. Physicochemical characterization of PW NPs; (a) SEM images of PW NPs, scale bar: 200 nm. (b) TEM images (scale bar: 200 nm) with inset particle size distribution of PW NPs. (c) UV–vis absorption spectra of wogonin and (d) the corresponding standard curve at 278 nm. (e) UV–vis absorption spectra of wogonin before and after loading into PLGA nanoparticles. (f) Hydrodynamic particle size distribution and zeta potential of PW NPs. (g) UV–vis absorption spectra of PLGA, WO, and PW NPs. (h) FTIR spectra of PLGA, WO, and PW NPs. (i) In vitro drug release profile of PW NPs. The Antitumor Efficiency of PW NPs WO is a natural flavonoid extracted from S. baicalensis, known for its potent antitumor properties, including antiproliferative, pro-apoptotic, and antimetastatic activities. , These characteristics have made WO a promising candidate for cancer therapy, particularly in targeting various tumor types, including OSCC. However, wogonin is a hydrophobic drug that is not suitable for direct injection, and concerns about the potential side effects of the free drug remain. PLGA nanoparticles, a well-established nanoparticulate drug delivery system, can effectively deliver hydrophobic drugs and enhance their cellular uptake. The enhanced permeability and retention (EPR) effect of nanoparticles also facilitates drug accumulation in tumor tissues, while the slow-release profile of PLGA nanoparticles helps prolong the therapeutic effect of the drug. Therefore, PLGA nanoparticles provide an ideal delivery system for wogonin. − In this study, the antitumor effects of PW NPs on Cal-27 cells, a commonly used OSCC cell line, were evaluated using several in vitro assays. The CCK-8 assay (Figure a) demonstrated that both free Wo and PW NPs exhibited dose-dependent cytotoxicity against Cal-27 cells at concentrations of 25, 50, 100, 200, and 300 μg/mL, corresponding to equivalent wogonin concentrations of 3.8, 7.6, 15.3, 30.6, and 46 μg/mL, respectively. As the concentration increased, cell viability progressively decreased. Interestingly, PW NPs showed the most significant inhibitory effect at 100 μg/mL compared to free WO, while at higher concentrations (200 and 300 μg/mL), free WO exhibited greater cytotoxicity. This dose-dependent effect suggests that the release profile of the nanoparticles and their mechanisms of action within the cells may differ from those of free WO, particularly at higher concentrations. Live/dead staining (Figure b) further confirmed these findings, showing a significant reduction in viable cells (green fluorescence) with increasing PW NP concentration, indicating a substantial decrease in cell survival. Flow cytometry analysis (Figure c) using Annexin V-APC/PI staining provided quantitative evidence of apoptosis. The combined percentage of apoptotic and necrotic cells increased in a concentration-dependent manner, rising from 0.29% in the control group to 9.97%, 17.94%, 29.83%, 31.80%, and 35.06% at 25, 50, 100, 200, and 300 μg/mL, respectively. These results indicate that PW NPs effectively reduce cell viability and promote apoptosis in Cal-27 cells, highlighting their potential as a novel therapeutic approach for OSCC. Antitumor efficiency of PW NPs; (a) The viability of Cal-27 cells incubated with PW NPs and free Wo at different concentrations. (b) Representative images of Cal-27 cells stained with Calcein-AM and PI after treatment with PW NPs at various concentrations (scale bar: 100 μm). (c) Flow cytometry analysis of apoptosis in Cal-27 cells using the Annexin V-APC/PI apoptosis detection kit after treatment with PW NPs at different concentrations. Effects of PW NPs on Cell Migration, Hemocompatibility, and Cytotoxicity in Normal Cells The effect of PW NPs on the migratory capacity of Cal-27 cells was assessed using a scratch test. Microscopic images (Figure a) were captured at 0, 24, and 48 h following treatment with PW NPs at concentrations of 0, 25, 50, 100, 200, and 300 μg/mL. At baseline (0 h), clear linear scratches were visible in all groups. Over time, the control group (0 μg/mL) showed substantial scratch closure, whereas the PW NPs-treated groups demonstrated progressively reduced migration with increasing concentrations. Quantitative analysis of the areas covered by cell growth at 24 h (Figure b) and 48 h (Figure c) was performed to compare the cell migration ability of CAL-27 cells in different treatment groups. The results showed that cells treated with 25, 50, and 100 μg/mL of PW NPs exhibited reduced migration. At 48 h, the 100 μg/mL PW NPs-treated CAL-27 cells exhibited almost no migration. Higher concentrations of PW NPs showed larger residual scratch areas than the initial scratch, indicating impaired closure ability. These findings suggest that PW NPs can effectively inhibit tumor cell migration while reducing their viability. Since cell migration is a critical step in tumor invasion and metastasis, the ability of PW NPs to suppress this process highlights their therapeutic relevance in limiting the progression of OSCC. The hemocompatibility of PW NPs was assessed through a hemolysis assay (Figure d). Red blood cells incubated with various concentrations of PW NPs remained intact, and hemolysis rates were consistently below 2%, well within the acceptable threshold for biomedical applications. This result demonstrates that PW NPs exhibit negligible hemolytic activity, supporting their safety for systemic administration and potential clinical use. Finally, the cytotoxicity of free Wogonin (Wo) and PW NPs toward normal human oral keratinocytes (HOK) was compared (Figure e). At lower concentrations, no significant difference in toxicity was observed between PW NPs and free wogonin. However, at higher concentrations, free wogonin exhibited greater toxicity compared to PW NPs. This difference can be attributed to the enhanced cellular uptake of PW NPs compared to the lipophilic free Wogonin, due to their nanoparticle formulation. At higher concentrations, the sustained-release properties of PW NPs resulted in reduced toxicity. These findings suggest that PW NPs can minimize the adverse effects of high-dose treatments while maintaining their anticancer efficacy, providing a safer therapeutic option for OSCC by reducing collateral damage to healthy tissues. Evaluation of the biological effects of PW NPs, including wound healing assay images of Cal-27 cells at 0, 24, and 48 h under different concentrations of PW NPs (a), quantitative analysis of wound areas at 24 h (b) and 48 h (c), hemolysis assay at various concentrations of PW NPs (d), and comparison of the cytotoxicity of Wo and PW NPs on HOK cells (e). Network Pharmacology Analysis Previous experiments demonstrated that Wo effectively inhibits OSCC cell proliferation, reduces survival, enhances apoptosis, and significantly reduces the invasive potential of OSCC cells. To explore the molecular mechanisms underlying Wo’s effects in OSCC, a network pharmacology approach was employed. Initially, 108 potential antitumor targets of Wo were identified from the PharmMapper database, with a Norm Fit score greater than 0.5. Additionally, 2592 OSCC-related targets were retrieved from the GeneCards database (Figure a). The intersection of these data sets identified 50 overlapping targets, suggesting they may mediate the therapeutic effects of Wo in OSCC (Figure a). These targets were then input into the STRING database to construct a protein–protein interaction (PPI) network (Figure b). After removing isolated nodes, a network consisting of 49 nodes and 304 edges, with an average node degree of 12.2, was obtained (Figure c). This indicates that Wo may act through multiple interconnected targets. Further analysis using the CytoHubba plugin in Cytoscape identified key targets, including AKT1, ESR1, EGFR, HSP90AA1, ALB, GSK3B, SRC, BRAF, PPARG, AR, MAPK14, CDK2, HSPA8, CCNA2, KDR, CHEK1, MET, PLAU, AURKA, and PTPN11. These core targets, exhibiting high interconnectivity, are likely central to the antitumor effects of Wo. This network pharmacology analysis provides comprehensive insights into the potential molecular mechanisms of Wo in OSCC and lays the foundation for further research into its clinical application. Network pharmacology analysis of Wo’s potential targets; (a) Venn diagram of the overlap between Wo’s predicted targets and OSCC-related targets. (b) PPI network of the 50 overlapping targets. (c) Core targets identified from the PPI network using the CytoHubba plugin in Cytoscape. KEGG Pathway Enrichment Analysis of Wo Targets in OSCC To further explore the molecular mechanisms underlying the antitumor effects of Wo in OSCC, KEGG pathway enrichment analysis was conducted on the 50 overlapping targets identified from the PharmMapper and GeneCards databases. The results revealed significant enrichment of these targets in several cancer-related pathways, including “Pathways in cancer”, “Proteoglycans in cancer”, “PI3K-AKT signaling pathway”, “Prostate cancer”, “Gastric cancer”, “EGFR tyrosine kinase inhibitor resistance”, “Progesterone-mediated oocyte maturation”, “Estrogen signaling pathway”, and “Epithelial cell signaling in Helicobacter pylori infection” (Figure a). These pathways are known to play crucial roles in tumor progression, metastasis, and therapy resistance, suggesting that Wo may modulate these biological processes to exert its therapeutic effects. KEGG pathway enrichment analysis of Wo’s targets; (a) KEGG enrichment bubble plot of the 50 overlapping targets. (b) KEGG pathway chord diagram of the enriched pathways and their specific targets. (c) Mapping of core targets to the key nodes of the EGFR tyrosine kinase inhibitor resistance pathway. Notably, the “EGFR tyrosine kinase inhibitor resistance” pathway (hsa01521) was particularly prominent, with core targets such as EGFR, KDR, MET, GSK3B, AKT1, SRC, and BRAF being enriched in this pathway (Figure b). These targets were highlighted in red in the KEGG pathway diagram, indicating their critical roles in the EGFR signaling pathway and their potential association with EGFR inhibitor resistance in OSCC (Figure c). Given the central role of EGFR in tumor progression, immune regulation, and therapy resistance, and considering the pivotal position of these targets in the enriched pathway, it is hypothesized that Wo may exert its antitumor effects by inhibiting the EGFR signaling pathway, potentially overcoming EGFR inhibitor resistance in OSCC. This finding emphasizes the potential of Wo as a therapeutic agent for OSCC and suggests that targeting EGFR could be a promising strategy to enhance the efficacy of current treatments. EGFR Pathway Target Expression in OSCC To investigate the expression of key targets in the EGFR signaling pathway in OSCC, the GSE23558 database was utilized to analyze the differential expression of core targets enriched in the hsa01521 pathway. The analysis revealed that only KDR, MET, and EGFR exhibited differential expression. A volcano plot (Figure a) was generated to visualize these expression differences. The results showed a significant upregulation of EGFR and MET in OSCC cells, while KDR was significantly downregulated. No significant changes were observed in the expression of BRAF, GSK3B, SRC, or AKT1. Given the crucial role of EGFR in tumor progression and its established importance as a therapeutic target, EGFR was prioritized for further analysis. Although MET and KDR also contribute to cancer progression, EGFR signaling is particularly vital in OSCC, and EGFR has been extensively studied as a key therapeutic target. Overexpression of EGFR is closely associated with increased invasiveness, resistance to therapy, and poor prognosis in OSCC. Therefore, the expression and modulation of EGFR were analyzed to assess the potential effects of Wo on this pathway. , Subsequently, qRT-PCR analysis of EGFR expression was conducted (Figure b). Compared to normal oral epithelial cells, EGFR expression was significantly higher in OSCC cells. This finding is consistent with previous network pharmacology and KEGG analysis results, suggesting that EGFR overexpression may contribute to OSCC progression. Based on cell viability and cell migration data, we selected 100 μg/mL as the concentration for subsequent studies primarily because further increasing the concentration of PW NPs resulted in a relatively smaller increase in cytotoxicity. After considering the balance between concentration and cytotoxicity effects, we determined that 100 μg/mL would be the optimal concentration for further research. Both Wo and PW NPs significantly downregulated EGFR mRNA levels in cell, with the PW NPs-treated group showing a more pronounced reduction in EGFR expression. This indicates that Wo, particularly when delivered via nanoparticle formulation, effectively reduces EGFR expression. The enhanced inhibitory effect observed with PW NPs can be attributed to their sustained-release formulation, which improves drug solubility, stability, and cellular uptake, leading to more efficient and sustained EGFR inhibition. These results support the hypothesis that EGFR inhibition plays a crucial role in Wo’s antitumor effects in OSCC. Expression of EGFR in Cal-27 cells; (a) Volcano plot of the differential expression of core targets in the has01521 pathway. (b) qRT-PCR analysis of EGFR expression in Cal-27 cells. Biocompatibility To assess the biocompatibility and potential toxicity of PW, blood samples were collected for complete blood count (CBC) analysis and serum biochemical testing (Figure a). The results indicated that the white blood cells (WBC) and red blood cells (RBC) in the PW NPs-treated group remained within normal ranges, with no abnormalities observed. Liver function markers (AST and ALT) and kidney function markers (CRE and URE) did not show significant differences compared to the control group, suggesting that PW NPs did not interfere with normal liver and kidney function. Additionally, histological analysis of major organs, including the heart, liver, spleen, lungs, and kidneys, was performed using hematoxylin and eosin (H&E) staining (Figure b). No abnormal findings or signs of toxicity, such as inflammation or necrosis, were observed in the tissues of the treated group. These results confirm that PW NPs, particularly in nanoparticle form, exhibit excellent biocompatibility and do not induce significant toxicity in major organs. Therefore, PW NPs demonstrate good in vivo biocompatibility and show potential for clinical application. Biocompatibility evaluation of PW NPs; (a) Study of serum biochemical and hematological indexes after different treatments (n = 3). (b) Hematoxylin and eosin (H&E) staining of major organs (heart, liver, spleen, lungs, and kidneys, scale bar: 20 μm). Conclusion This study successfully prepared PW NPs that enhanced the water solubility of Wo and endowed the material with sustained-release properties, thereby significantly improving its antitumor effects against OSCC. Although Wo has shown therapeutic efficacy in various tumor types, its role in OSCC remains unexplored. This study addresses this gap by systematically evaluating the antitumor effects and mechanisms of PW NPs in OSCC. Cell viability assays, flow cytometry, live/dead staining, and wound-healing assays demonstrated that PW NPs significantly inhibited the proliferation and cell migration of Cal-27 cells and induced apoptosis, thereby exerting antitumor effects. Network pharmacology and KEGG enrichment analysis revealed the pivotal role of the EGFR signaling pathway in Wo’s antitumor action. PW NPs showed a more pronounced impact on downregulating EGFR expression than Wo. Biocompatibility assessments confirmed that PW NPs did not induce significant toxicity in mice, demonstrating good biocompatibility. In conclusion, this study provides the first evidence of the antitumor effects of Wo in OSCC, and the PLGA nanoparticle formulation enhances its therapeutic efficacy, presenting a novel and promising strategy for OSCC treatment.